Category: Peptide Q&A

What is the half-life of AHK-Cu in human serum when administered topically, and how does it distribute in tissues?

Does AHK-Cu influence insulin signaling pathways or glucose metabolism in human or animal models, and what is the proposed mechanism for such effects?

How does AHK-Cu influence the expression of genes related to angiogenesis, such as VEGF, in dermal tissue?

What are the findings from animal toxicology studies on AHK-Cu, particularly regarding liver and kidney function after chronic exposure?

What is the optimal concentration and application frequency of AHK-Cu in topical formulations for maximal dermal efficacy, based on clinical and preclin

What is the role of AHK-Cu in modulating inflammation during the wound healing process, particularly in reducing pro-inflammatory cytokines like IL-6 an

How do clinical studies on AHK-Cu measure changes in dermal thickness and collagen density using non-invasive imaging (e.g., high-frequency ultrasound)?

What are the potential adverse effects of long-term topical or systemic AHK-Cu exposure, particularly concerning copper accumulation and oxidative stres

Can AHK-Cu improve skin hydration and barrier function, and what is the evidence from transepidermal water loss (TEWL) measurements?

How does AHK-Cu compare to niacinamide in reducing inflammatory acne lesions and improving skin barrier function?